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ABSTRACT
The influence of alpha and beta cells, through
glucagon and insulin, on energy metabolism is
well known. The insulin:glucagon ratio (IGR) is
a frequently discussed entity in the medical
literature. However, in recent years, focus has
shifted to other pathways and markers of health
and disease. This communication revisits the
insulin:glucagon bipolar axis and describes the
significance of the IGR. It reviews the effects of
various glucose-lowering drugs on this ratio,
and hypothesizes that the ratio can be used to
predict the appropriate choice of drugs for
managing diabetes. Drugs which increase the
IGR may be beneficial in insulinopenic
conditions, while those which decrease IGR
may be of help in the setting of
hyperinsulinemia or insulin resistance.
Keywords: Antidiabetic drugs; Glucagon;
Insulin; Insulin:glucagon ratio; Therapy choice
THE INSULIN:GLUCAGON BIPOLAR
AXIS
Glucagon and insulin are two opposing
hormones which work in tandem to maintain
a normal fuel balance. By modulating the
relative concentrations of glucagon and
insulin, the alpha and beta cells of the
pancreas control endogenous glucose
production, triacylglycerol deposition, and
protein synthesis [1]. In simple terms,
glucagon acts as a catabolic hormone, while
insulin exerts anabolic effects on the body. A
low insulin:glucagon ratio (IGR) stimulates
mobilization of stored nutrients, increases
glycogenolysis and gluconeogenesis, and
promotes the breakdown of adipose tissue into
free fatty acids and glycerol. A high IGR
encourages biosynthesis of proteins, inhibits
the production of glucose, and reduces free fatty
acid release [2]. The effects of insulin and
glucagon on various physiological processes
are listed in Table 1.
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This aspect of physiology is not, however,
highlighted adequately in diabetology circles and
texts.ThoughDefronzo [3] included thealphacell
aspartof theominousoctet, andSchwartz etal. [4]
list it as one of the egregious eleven, less attention
has been paid to this pathophysiologic player.
Some reasons for this may be the multitude of
factors which affect insulin and glucagon
secretion, their highly variable concentrations,
the existence of a significant, and variable,
porto-systemic gradient, and the difficulty
involved in estimating them. In spite of
extensive research, there is still controversy
surrounding the absolute concentrations of
insulin and glucagon in persons with diabetes.
Yet another explanation may be the current
interest in nonpancreatic pathophysiological
pathways of diabetes. This article does not
contain any new studies with human or animal
subjects performed by any of the authors.
INSULIN
Ambient insulin concentrations present a
spectrum of values, ranging from absolute
deficiency in type 1 diabetes to
hyperinsulinemia in those with type 2
diabetes. Beta-cell secretory capacity is known
to fall with increasing duration of diabetes, so
insulin levels may vary depending upon
diabetes stage. Insulin levels are also reported
to be high in obese persons, irrespective of
glycemic status. This is a reflection of the
insulin resistance that occurs with obesity.
Insulin levels vary with meals, with specific
nutrients, and with comorbid conditions.
Insulinogenic stimuli, for example, include
glucose as well as certain amino acids
(Table 2). Alterations in growth hormone and
thyroid hormone secretion also affect insulin
secretion. In man, a first phase and a second
Table 1 Biochemical effects of insulin and glucagon
Process Insulin Glucagon
Glycogenesis Increased (glycogen synthase activation) Inhibited (glycogen synthase deactivation)
Gluconeogenesis Inhibited (inhibition of pyruvate carboxylase,
phosphoenolpyruvate carboxykinase, glucose
6 phosphatase)
Increased (inhibition of pyruvate kinase,
phosphofructokinase; activation of fructose
1,6-bisphosphatase)
Glycolysis Increased (activation of glucokinase,
phosphofructokinase, pyruvate kinase)
Glycogenolysis Inhibited (inhibition of glycogen
phosphorylase)
Increased (activation of glycogen
phosphorylase)




Lipogenesis Increased (more substrate glycerol 3 phosphate
and nicotinamide adenine dinucleotide
phosphate (NADPH); activation of acetyl
CoA carboxylase)
Protein synthesis Decreased protein degradation Increased amino acid uptake by liver; decreased
amino acids in plasma
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phase of insulin can easily be identified, along
with distinct basal and prandial secretion [5]. In
some primates, insulin is released in oscillations
which occur at intervals of roughly 9 min [6].
This phenomenon is not seen in humans.
GLUCAGON
Glucagon secretion varies from the fasting to
the postprandial state according to the
composition of the meal taken, and is
influenced by body weight as well as comorbid
illnesses [7, 8]. There are varying opinions about
the concentration of glucagon in obesity and—
just like diabetes—current research suggests that
glucagon, or glucagon response to arginine,
increases in obesity. Glucagon levels are higher
in diabetes, increase on stimulation with
arginine, and are not suppressed after glucose
administration. Workers also suggest a
resistance to glucagon in obese persons with
diabetes [9].
The issue is also complicated by issues
associated with the assessment of insulin and
glucagon. Various researchers estimate a variety
of species, such as C-peptide, insulin, pancreatic
glucagon, enteroglucagon, and immunoreactive
glucagon. Altered tissue response to insulin and
glucagon is also reported in obesity, raising the
question of whether the determination of
absolute glucagon values is worth the effort.
Yet another controversy relates to the systemic
and portal concentrations of these antipodal
hormones. As the portosystemic gradients of
insulin and glucagon are dissimilar, the
relevance of testing peripheral IGR is also
doubtful [10, 11].
INSULIN:GLUCAGON RATIO
The insulin:glucagon bipolar axis serves to
regulate carbohydrate and lipid metabolism.
The therapeutic value of glucagon in diabetes
management is gradually becoming clear [12].
As these hormones work in tandem with each
other, albeit in opposing directions, it may
make sense to interpret the IGR instead of
assessing absolute values. This concept was
popularized by Unger [1], who proposed the
bihormonal hypothesis. The IGR has been
found to vary with the presence of, or the
need for, anabolism and catabolism. The IGR
varies inversely with the need for endogenous
glucose production. It is lowest in total
starvation and highest during loading with
exogenous carbohydrate. The molecular
mechanisms which control this energy
homeostasis are listed in Table 1. In brief, the
IGR acts as a physiological fulcrum, balancing
two opposite ends of the metabolic spectrum to
provide energy when needed and conserve it if
possible.
GLUCOSE-LOWERING DRUGS
Recent years have witnessed the development
of various classes of glucose-lowering drugs.
These molecules are studied for their effect on a
wide range of glucotropic hormones and
metabolites, apart from their direct effect on
Table 2 Physiological determinants of insulin and glucagon secretion
Insulin Glucagon
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glucose lowering. The effect of various
glucose-lowering drugs on insulin levels is well
known, but their effect on glucagon levels, and
specifically on the IGR, is rarely discussed. This
is unfortunate, as detailed insight into this
aspect of pharmacodynamics may aid the
selection of the appropriate therapy for each
patient based upon their insulin-glucagon
homeostasis. Drugs which increase the IGR
may be beneficial in insulinopenic conditions,
while those which decrease the IGR may be of
help in the setting of hyperinsulinemia or
insulin resistance.
Recent studies have shown that metformin
therapy does not lead to any change in
glucagon secretion [12]. However, the
insulin-sensitizing effect of metformin causes a
reduction in hyperinsulinemia, and thus
reduces the IGR. Similar effects are reported
with pioglitazone [13].
Sulfonylureas such as glimepiride are
insulinotropic agents which increase insulin
secretion but have no impact whatsoever on
alpha cell function or glucagon secretion. Thus,
glimepiride certainly increases the IGR. In
another study, glimepiride was found to increase
both prandial insulin as well as prandial glucagon
[area under curve (AUC), 0–2 h] [14]. The
opposing effects of insulin sensitizers and
insulin secretagogues are visible at the molecular
level as well.Whilemetformin activates carnitine
palmitoyltransferase 1 (CPT1), glibenclamide
inhibits this enzyme [15, 16]. This molecular
difference may explain the effects of these drugs
on weight: metformin promotes b-oxidation of
free fatty acids, while glibenclamide facilities
triacylglycerol production.
The incretin-based therapies are, in general,
thought to reduce plasma glucagon levels. The
evidence reveals variable effects. Recently,
liraglutide, a glucagon-like peptide-1 receptor
agonist (GLP1RA), has been shown to increase
post-challenge glucagon levels after 12 weeks of
therapy, though no such effects were noted after
shorter periods of treatment. This effect persisted
for 48 weeks (the duration of the trial), but was
not noted in the fasting state [17]. Tachyphylaxis
has been suggested as a possible mechanism to
explain this phenomenon [18]. Other studies
have demonstrated no effect of liraglutide on
fasting glucagon, but have noted its ability to
reduce 24-h glucagon levels (by reducing
glucagon secretion after a protein-rich meal)
[19]. The authors reported no change in the IGR
with liraglutide therapy. However, in a Japanese
study, liraglutide increased the IGR. While the
drug reduced the incremental release of glucagon
between 15 and 60 min after a meal, it did not
change overall glucagon secretion. Coupledwith
an increase in insulin secretion, this led to an
increase in the IGR with liraglutide [20].
A 28-day-long pharmacodynamics study
compared the effect of lixisenatide and
liraglutide on plasma insulin and glucagon
concentrations, but did not statistically
analyze the IGR [21]. Lixisenatide provided a
significantly greater decrease in postprandial
glucagon as compared to liraglutide.
Postprandial insulin and C-peptide levels were
also significantly reduced with lixisenatide
versus liraglutide [21], while decreases in
proinsulin were comparable between groups.
The trend was for a higher IGR with liraglutide
and a lower one with lixisenatide. In individuals
without diabetes, exenatide increased the IGR
at rest, but this trend reversed when exercise
was performed [22]. A lowering of plasma
glucagon was noted in individuals with type 2
diabetes with the same drug [23]. Dulaglutide, a
once-weekly GLP1RA reduces fasting glucagon
concentrations while increasing homeostatic
model assessment 2 beta (HOMA2B). This
implies that dulaglutide administration
increases the IGR [12].
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Relative to the dipeptidyl peptidase inhibitor
sitagliptin, exenatide has been shown to
increase the IGR [24]. However, in absolute
terms, sitagliptin also increases insulin secretion
and reduces glucagon concentrations, thus
causing a rise in the IGR. Vildagliptin, another
dipeptidyl peptidase inhibitor, decreases
prandial glucagon AUC (0–2 h). This effect has
been reported to persist for at least 2 years, and
reflects the improved alpha cell sensitivity
caused by vildagliptin. Vildagliptin also
increases insulin secretion, though not to the
same extent as glimepiride. In total, vildagliptin
increases the IGR [13]. Similar effects are noted
with linagliptin and saxagliptin [25, 26].
Empagliflozin, a sodium glucose
co-transporter-2 (SGLT2) inhibitor, has
recently been shown to reduce the IGR. This
effect is pronounced after acute administration
of the drug, but persists—to an attenuated
degree—after 28-day exposure. This reduction
in the IGR reflects an increased need for—and
an actual increase in—endogenous glucose
production, to balance the increase in
glucosuria. Similar results have been reported
with dapagliflozin (Table 3) [27, 28]. The
possible reasons for this phenomenon have
been hypothesized in detail [29].
No significant differences in serum insulin
and plasma glucagon levels were documented
after 1 week of colestimide administration [30].
Acarbose, an alpha-glucosidase inhibitor,
reduces serum insulin levels without
influencing glucagon secretion, and thus
reduces the IGR [31].
IMPACT ON WEIGHT GAIN
AND HYPOGLYCEMIA
Weight gain and hypoglycemia are common
but unwanted corollaries of conventional
glucose-lowering therapy. However, newer
classes of drugs offer the advantage of weight
loss along with glycemic control while also
avoiding hypoglycemia. In general, drugs which
increase the IGR will be associated with an
anabolic effect or tendency for weight gain and
an increased risk of hypoglycemia. On the other
hand, drugs which reduce the IGR will facilitate
weight loss and prevent hypoglycemia. Our
IGR-based construct is concordant with the
clinical pharmacology of directly acting
insulin secretagogues such as sulfonylureas
(which increase the IGR, may cause weight
gain, and are associated with hypoglycemia)
and novel drugs like GLP1RA and SGLT2
inhibitors (which reduce the IGR, aid weight
loss, and are associated with a minimal risk of
hypoglycemia).





Glimepiride : No change :





Dulaglutide : ; :
Exenatide : ; :
Lixisenatide ; ; ;
Dapagliﬂozin : : ;
Metformin ; No change ;
Pioglitazone ; – ;
Acarbose ; No change ;
Based upon [11–14, 16, 18–22, 24–27]
; = reduction; : = increase
DPP4i dipeptidyl peptidase-4 inhibitor, IGR
insulin:glucagon ratio
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THERAPEUTIC IMPLICATIONS
In spite of the increasing number of molecules
available for diabetes management, glycemic
control remains suboptimal. A large number of
people with diabetes continue to be classified as
‘‘refractory’’ or unresponsive to treatment. Even
in the best randomized controlled trials, a
significant proportion of subjects remain
nonresponders to allocated therapy. There is
also a dearth of studies that are able to
differentiate responders and nonresponders
based upon their demographic characteristics,
physical attributes, or biochemical phenotype.
Thus, there is still an unmet need to explore and
identify biochemical markers which may serve
as predictors of response to chosen therapeutic
interventions.
The IGR, therefore, may be used to create a
matrix for choosing an antidiabetic therapy.
Though data are limited and may be conflicting,
one can create a model, based upon absolute
and relative values of insulin and glucagon, to
facilitate the selection of the appropriate
therapy (Fig. 1). Persons with high insulin
levels(hyperinsulinemia, secondary to insulin
resistance) will benefit from drugs which lower
insulin secretion (insulin sensitizers, SGLT2
inhibitors, alpha-glucosidase inhibitors).
Within this group of patients, those with low
glucagon values may respond better to SGLT2
inhibitors. Incretin-based therapy has been
shown to be more effective in persons with
high glucagon levels [32]. As these modes of
treatment cause hyperinsulinemia,
incretin-based therapy may prove more
suitable for persons with a normal IGR.
Glimepiride may be a better choice for persons
with low insulin and a low IGR. The effects of
metformin and SGLT2 inhibitors on the IGR are
similar to those seen with calorie restriction.
Thus, clinical situations requiring calorie
restriction mimicry (e.g., obese diabetes; need
for geroprotection) [33] may benefit from these
drug classes.
Rational combinations may also be created
using knowledge of the effects of drugs on
insulin and glucagon. For example, it may be
beneficial to combine incretin-based therapy,
which reduces glucagon concentrations, with
SGLT2 inhibitors, which are known to increase
glucagon.
It is not our suggestion that IGR estimation
becomes an integral part of routine diabetes
care; it is, and will remain, a research tool.
However, clinical endocrinologists should
understand this physiological concept and be
able to translate it into an appropriate choice of
pharmacotherapy. Preclinical and clinical
development programs for modern drugs
Fig. 1 Choice of glucose-lowering therapy based upon the
IGR. X-axis: IGR; y-axis: insulin concentration. AGI
alpha-glucosidase inhibitors, DPP4i dipeptidyl peptidase-4
inhibitor, GLP1RA glucagon-like peptide-1 receptor ago-
nist, IGR insulin:glucagon ratio, SGLT2i sodium glucose
transporter-2 inhibitor
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should include detailed study of their effects on
the insulin:glucagon axis: this will help to
unravel new facets of human biochemistry
and physiology.
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